NASDAQ:MDRX - Allscripts Stock Price, Price Target & More

$12.23 -0.09 (-0.73 %)

(As of 04/24/2018 08:36 AM ET)

Previous Close$12.32

Today's Range$12.19 - $12.46

52-Week Range$10.78 - $16.13

Volume709,300 shs

Average Volume1.94 million shs

Market Capitalization$2.19 billion

P/E Ratio26.02

Dividend YieldN/A

Beta1.23

About Allscripts (NASDAQ:MDRX)

Allscripts Healthcare Solutions, Inc. provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company's Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services. Its Population Health segment offers health management and coordinated care solutions that enable hospitals, health systems, accountable care organizations, and other care facilities to connect, transition, analyze, and coordinate care across the entire care community. The company's Netsmart segment operates in and provides software and technology solutions to the health and human services, and post-acute sectors of health care. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Receive MDRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Computer integrated systems design

Sub-IndustryHealth Care Technology

SectorMedical

SymbolNASDAQ:MDRX

CUSIP01988P10

Webwww.allscripts.com

Phone312-506-1200

Debt

Debt-to-Equity Ratio1.33%

Current Ratio0.97%

Quick Ratio0.97%

Price-To-Earnings

Trailing P/E Ratio26.02

Forward P/E Ratio21.84

P/E Growth1.59

Sales & Book Value

Annual Sales$1.81 billion

Price / Sales1.20

Cash Flow$1.6708 per share

Price / Cash7.32

Book Value$6.42 per share

Price / Book1.90

Profitability

EPS (Most Recent Fiscal Year)$0.47

Net Income$-152,600,000.00

Net Margins-10.88%

Return on Equity7.36%

Return on Assets2.19%

Miscellaneous

Employees8,900

Outstanding Shares177,950,000

How to Become a New Pot Stock Millionaire

Allscripts (NASDAQ:MDRX) Frequently Asked Questions

What is Allscripts' stock symbol?

Allscripts trades on the NASDAQ under the ticker symbol "MDRX."

How were Allscripts' earnings last quarter?

Allscripts (NASDAQ:MDRX) issued its earnings results on Thursday, February, 15th. The software maker reported $0.18 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $0.18. The software maker had revenue of $547 million for the quarter, compared to analysts' expectations of $524.05 million. Allscripts had a positive return on equity of 7.36% and a negative net margin of 10.88%. The company's revenue was up 27.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.14 earnings per share. View Allscripts' Earnings History.

When is Allscripts' next earnings date?

Allscripts is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Allscripts.

What guidance has Allscripts issued on next quarter's earnings?

Allscripts issued an update on its FY18 earnings guidance on Thursday, February, 15th. The company provided EPS guidance of $0.72-0.82 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.79. The company issued revenue guidance of $2.15-2.25 billion, compared to the consensus revenue estimate of $2.15 billion.

What price target have analysts set for MDRX?

17 brokerages have issued twelve-month target prices for Allscripts' stock. Their predictions range from $12.00 to $20.00. On average, they anticipate Allscripts' share price to reach $16.3438 in the next year. View Analyst Ratings for Allscripts.

What are Wall Street analysts saying about Allscripts stock?

Here are some recent quotes from research analysts about Allscripts stock:

1. Cantor Fitzgerald analysts commented, "Today, MDRX filed an 8-K indicating that Netsmart has acquired the homecare software business from Change Healthcare for $167.5 million." (4/5/2018)
2. According to Zacks Investment Research, "Allscripts has had a favorable run on the bourses over the last year, trading above the broader industry. The company’s solid growth in U.S. Core Solutions and Services holds promise at the moment. Allscripts Sunrise electronic health record (EHR) platform and Revenue Cycle Management Services are likely to drive the company’s top line in the quarters to come. Also, Allscripts has a leading market share in inpatient and ambulatory settings. Allscripts announced a definitive agreement to buy Practice Fusion for $100 million in cash. However, the company’s continued reliance on mergers and acquisition activities poses substantial integration risks. Intensifying competition is a major dampener. The company’s products have a long sales cycle which involves intensive decision-making at different managerial levels. Allscripts also expects a modest increase in operating expenses to support business growth over the long haul." (1/25/2018)
3. Maxim Group analysts commented, "MDRX announced the acquisition of Practice Fusion, a provider of cloud- based electronic health record (EHR) platforms, for $100M in cash. The acquisition is expected to close in 1Q18. We believe Practice Fusion was sold at 1.0x-2.0x revenue, implying a $50M- $100M revenue run rate. It is expected to be marginally accretive in 2018. We estimate that the company’s recently-acquired Enterprise Information Systems (EIS) business is operating at a roughly $400M-$450M revenue run rate, significantly above our original estimate of $300M. We believe attrition in the EIS business may be lower than originally projected." (1/9/2018)

Are investors shorting Allscripts?

Allscripts saw a increase in short interest in March. As of March 29th, there was short interest totalling 17,204,055 shares, an increase of 29.0% from the March 15th total of 13,337,504 shares. Based on an average daily trading volume, of 1,946,518 shares, the short-interest ratio is currently 8.8 days. Currently, 9.7% of the shares of the company are sold short.

Who are some of Allscripts' key competitors?

Some companies that are related to Allscripts include CSRA (CSRA), Scientific Games (SGMS), CACI (CACI), Science Applications International (SAIC), Verint Systems (VRNT), Ebix (EBIX), NetScout Systems (NTCT), Convergys (CVG), Sykes Enterprises (SYKE), Quality Systems (QSII), VASCO Data Security International (VDSI), Unisys (UIS), Ribbon Communications (RBBN), The Keyw (KEYW) and Digimarc (DMRC).

Who are Allscripts' key executives?

Allscripts' management team includes the folowing people:

Mr. Paul M. Black, CEO & Director (Age 60)
Mr. Richard J. Poulton, Pres (Age 53)
Mr. Dennis M. Olis, Chief Financial Officer (Age 55)
Mr. Brian P. Farley, Exec. VP, Gen. Counsel & Chief Admin. Officer (Age 48)
Mr. James R. Hewitt, Exec. VP, Solutions Devel. (Age 51)

Has Allscripts been receiving favorable news coverage?

News headlines about MDRX stock have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allscripts earned a media sentiment score of 0.13 on Accern's scale. They also gave media coverage about the software maker an impact score of 49.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Allscripts?

Shares of MDRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allscripts' stock price today?

One share of MDRX stock can currently be purchased for approximately $12.23.

How big of a company is Allscripts?

Allscripts has a market capitalization of $2.19 billion and generates $1.81 billion in revenue each year. The software maker earns $-152,600,000.00 in net income (profit) each year or $0.47 on an earnings per share basis. Allscripts employs 8,900 workers across the globe.

How can I contact Allscripts?

Allscripts' mailing address is 222 MERCHANDISE MART SUITE 2024, CHICAGO IL, 60654. The software maker can be reached via phone at 312-506-1200 or via email at [email protected]

MarketBeat Community Rating for Allscripts (MDRX)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		476 (Vote Outperform)
Underperform Votes:		472 (Vote Underperform)
Total Votes:		948

MarketBeat's community ratings are surveys of what our community members think about Allscripts and other stocks. Vote "Outperform" if you believe MDRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Allscripts (NASDAQ:MDRX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

17 Wall Street analysts have issued ratings and price targets for Allscripts in the last 12 months. Their average twelve-month price target is $16.3438, suggesting that the stock has a possible upside of 33.64%. The high price target for MDRX is $20.00 and the low price target for MDRX is $12.00. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.65	2.63	2.56	2.56
Ratings Breakdown:	1 Sell Rating(s) 4 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$16.3438	$16.3667	$15.7667	$15.00
Price Target Upside:	33.64% upside	14.53% upside	3.05% upside	8.54% upside

Allscripts (NASDAQ:MDRX) Consensus Price Target History

Price Target History for Allscripts (NASDAQ:MDRX)

Allscripts (NASDAQ:MDRX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2018	JPMorgan Chase	Initiated Coverage	Buy	$16.00	Low
4/5/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$18.00	Low
2/27/2018	Bank of America	Initiated Coverage	Buy -> Buy	$17.00	Low
2/17/2018	Wells Fargo	Set Price Target	Buy	$19.00	High
1/18/2018	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$17.50	Medium
1/16/2018	SunTrust Banks	Downgrade	Buy -> Hold		High
1/11/2018	Royal Bank of Canada	Set Price Target	Buy	$19.00	High
1/9/2018	Maxim Group	Reiterated Rating	Buy	$20.00	Medium
1/4/2018	Citigroup	Initiated Coverage	Buy		Low
11/3/2017	Robert W. Baird	Boost Price Target	Outperform	$16.00 -> $17.00	N/A
10/27/2017	KeyCorp	Reiterated Rating	Hold		N/A
10/3/2017	Dougherty & Co	Reiterated Rating	Buy	$15.00 -> $16.00	Low
9/11/2017	Cowen	Upgrade	Market Perform -> Outperform	$13.00 -> $16.00	High
8/25/2017	Jefferies Group	Set Price Target	Buy	$17.00	Low
8/7/2017	Morgan Stanley	Boost Price Target	Underweight	$11.00 -> $12.00	Low
7/21/2017	Piper Jaffray	Reiterated Rating	Hold	$14.00	Low
6/19/2017	Leerink Swann	Downgrade	Outperform -> Market Perform	$15.00 -> $13.00	Medium
3/24/2017	Deutsche Bank	Upgrade	Hold -> Buy	$12.50 -> $14.00	Low
2/17/2017	Oppenheimer	Reiterated Rating	Hold		N/A
1/8/2017	FBR & Co	Reiterated Rating	Hold	$12.00	N/A
1/3/2017	Canaccord Genuity	Reiterated Rating	Buy	$17.00	N/A
10/23/2016	Argus	Reiterated Rating	Buy	$19.00	N/A
10/5/2016	UBS	Initiated Coverage	Buy	$17.00	N/A
8/5/2016	Goldman Sachs	Boost Price Target	Neutral	$14.00 -> $16.00	N/A

(Data available from 4/24/2016 forward)

Allscripts (NASDAQ:MDRX) Earnings History and Estimates Chart

Earnings by Quarter for Allscripts (NASDAQ:MDRX)

Allscripts (NASDAQ:MDRX) Earnings Estimates

2018 EPS Consensus Estimate: $0.57

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.11	$0.13	$0.12
Q2 2018	2	$0.13	$0.14	$0.14
Q3 2018	2	$0.15	$0.15	$0.15
Q4 2018	2	$0.16	$0.16	$0.16

Allscripts (NASDAQ MDRX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$0.17					N/A
2/15/2018	Q4 2017	$0.18	$0.18	$524.05 million	$547.00 million	View	Listen
11/2/2017	Q3 2017	$0.12	$0.12	$429.94 million	$451.20 million	View	N/A
8/3/2017	Q2 2017	$0.15	$0.11	$424.94 million	$426.10 million	View	Listen
5/4/2017	Q1 2017	$0.09	$0.10	$415.20 million	$415.00 million	View	Listen
2/16/2017	Q4 2016	$0.1530	$0.14	$424.11 million	$425.40 million	View	Listen
11/3/2016	Q3	$0.15	$0.14	$414.92 million	$392.40 million	View	Listen
8/4/2016	Q2	$0.14	$0.14	$403.13 million	$386.50 million	View	Listen
5/5/2016	Q1	$0.12	$0.13	$348.51 million	$346.00 million	View	Listen
2/18/2016	Q4	$0.13	$0.13	$357.91 million	$345.60 million	View	Listen
11/5/2015	Q315	$0.12	$0.13	$354.67 million	$355.00 million	View	Listen
8/4/2015	Q215	$0.11	$0.12	$347.13 million	$351.70 million	View	Listen
5/7/2015	Q115	$0.09	$0.08	$344.73 million	$335.00 million	View	Listen
2/26/2015	Q414	$0.09	$0.09	$358.10 million	$343.00 million	View	Listen
11/6/2014	Q314	$0.10	$0.06	$353.00 million	$348.00 million	View	Listen
8/7/2014	Q214	$0.09	$0.09	$353.12 million	$351.30 million	View	Listen
5/8/2014	Q114	$0.07	$0.07	$347.98 billion	$340.30 billion	View	Listen
2/20/2014	Q413	$0.08	$0.08	$343.47 million	$351.00 million	View	Listen
11/7/2013	Q313	$0.08	$0.05	$355.30 million	$334.00 million	View	Listen
8/8/2013	Q2 2013	$0.11	$0.09	$360.00 million	$344.80 million	View	Listen
5/9/2013	Q1 2013	$0.14	$0.09	$368.11 million	$347.10 million	View	Listen
2/19/2013	Q4 2012	$0.21	$0.16	$367.07 million	$367.70 million	View	Listen
11/8/2012	Q312	$0.22	$0.23	$376.97 million	$361.00 million	View	N/A
8/8/2012		$0.18	$0.16			View	N/A
4/26/2012		$0.24	$0.12			View	N/A
2/16/2012		$0.25	$0.25			View	N/A
11/3/2011		$0.22	$0.25			View	N/A
8/2/2011		$0.21	$0.22			View	N/A
5/5/2011		$0.20	$0.21			View	N/A
2/15/2011		$0.18	$0.20			View	N/A
11/8/2010	Q3 2010	$0.16	$0.17			View	N/A
7/20/2010	Q2 2010	$0.15	$0.15			View	N/A
4/7/2010	Q1 2010	$0.14	$0.14			View	N/A
1/10/2010	Q4 2009	$0.13	$0.14			View	N/A
9/29/2009	Q3 2009	$0.13	$0.14			View	N/A
7/20/2009	Q2 2009	$0.14	$0.15			View	N/A
4/2/2009	Q1 2009	$0.12	$0.14			View	N/A
1/8/2009	Q4 2008	$0.12	$0.14			View	N/A
10/23/2008	Q3 2008	$0.13	$0.13			View	N/A
8/5/2008	Q2 2008	$0.09	$0.11			View	N/A
4/30/2008	Q1 2008	$0.10	$0.07			View	N/A
2/13/2008	Q4 2007	$0.12	$0.14			View	N/A

(Earnings results data provided by Zacks Investment Research)

Allscripts (NASDAQ:MDRX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Allscripts (NASDAQ MDRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%

Insider Trading History for Allscripts (NASDAQ:MDRX)

Institutional Ownership by Quarter for Allscripts (NASDAQ:MDRX)

Allscripts (NASDAQ MDRX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	Richard J Poulton	President	Sell	15,000	$13.53	$202,950.00	505,920
3/14/2018	Brian Farley	EVP	Sell	5,000	$13.73	$68,650.00	240,672
12/15/2017	Richard J Poulton	President	Sell	15,000	$14.26	$213,900.00	1,351,773
12/14/2017	Brian Farley	EVP	Sell	5,000	$14.35	$71,750.00	191,607
12/1/2017	James Hewitt	SVP	Sell	36,796	$14.11	$519,191.56	181,766
9/15/2017	Richard J. Poulton	President	Sell	15,000	$13.56	$203,400.00
9/14/2017	Brian Farley	EVP	Sell	5,000	$13.52	$67,600.00	196,607
9/14/2017	Paul Black	CEO	Sell	15,000	$13.52	$202,800.00
5/16/2017	Richard J Poulton	President	Sell	25,000	$12.06	$301,500.00	412,488
3/23/2017	Brian Farley	SVP	Sell	15,000	$11.63	$174,450.00	217,861
9/15/2016	James Hewitt	SVP	Sell	17,500	$13.00	$227,500.00	158,104
9/15/2016	Paul Black	CEO	Sell	15,000	$13.00	$195,000.00	1,177,009
7/11/2016	Dennis Olis	SVP	Sell	7,000	$14.00	$98,000.00	210,887
7/1/2016	James Hewitt	SVP	Sell	17,500	$13.00	$227,500.00	175,604
6/13/2016	Paul Black	CEO	Sell	15,000	$13.04	$195,600.00	1,197,329
6/13/2016	Richard J Poulton	President	Sell	10,000	$13.03	$130,300.00	343,813
4/7/2016	Dennis Olis	SVP	Sell	25,000	$14.00	$350,000.00	217,887
3/30/2016	James Hewitt	SVP	Sell	17,500	$13.31	$232,925.00	228,104
3/30/2016	Paul Black	CEO	Sell	15,000	$13.31	$199,650.00	1,224,939
3/14/2016	Richard J Poulton	President	Sell	5,000	$12.85	$64,250.00	359,064
8/17/2015	James Hewitt	SVP	Sell	70,000	$14.17	$991,900.00
12/12/2014	Paul Black	CEO	Buy	6,500	$11.51	$74,815.00
11/18/2014	Anita Pramoda	Director	Buy	2,017	$12.25	$24,708.25
11/13/2014	Dennis Chookaszian	Director	Buy	10,000	$12.43	$124,300.00
11/11/2014	Dennis Olis	SVP	Buy	4,400	$11.26	$49,544.00
11/11/2014	Paul Black	CEO	Buy	22,180	$11.26	$249,746.80
11/11/2014	Richard J Poulton	CFO	Buy	4,500	$11.26	$50,670.00
11/11/2014	Stuart L Bascomb	Director	Buy	6,743	$11.26	$75,926.18
8/18/2014	Michael Klayko	Director	Buy	3,500	$14.41	$50,435.00
3/13/2014	Deborah Snow	SVP	Sell	14,740	$18.75	$276,375.00	32,560
11/21/2013	Deborah Snow	SVP	Sell	2,400	$14.70	$35,280.00	33,655
9/9/2013	Clifford B Meltzer	EVP	Sell	35,000	$14.56	$509,600.00
8/15/2013	Michael Klayko	Director	Buy	10,000	$14.80	$148,000.00	24,225
5/30/2013	Deborah Snow	SVP	Sell	1,495	$13.71	$20,496.45
5/20/2013	Stuart L Bascomb	Director	Buy	3,701	$14.02	$51,888.02
5/15/2013	Paul Black	CEO	Buy	7,120	$14.02	$99,822.40
5/14/2013	Steve Shute	VP	Sell	14,612	$14.10	$206,029.20
3/12/2013	Paul Black	CEO	Buy	23,625	$12.69	$299,801.25
3/12/2013	Stuart L Bascomb	Director	Buy	10,000	$12.64	$126,400.00

(Data available from 1/1/2013 forward)

Allscripts (NASDAQ MDRX) News Headlines

Source:

Date	Headline
	JPMorgan Assumes Allscripts (MDRX) at Overweight www.streetinsider.com - April 24 at 8:28 AM
	Technical Perspectives on Application Software Stocks -- 2U, Allscripts Healthcare Solutions, Alteryx, and ANSYS www.prnewswire.com - April 23 at 8:24 AM
	Analysts Expect Allscripts (MDRX) Will Announce Quarterly Sales of $532.66 Million www.americanbankingnews.com - April 19 at 4:57 AM
	Zacks: Brokerages Anticipate Allscripts (MDRX) Will Post Earnings of $0.17 Per Share www.americanbankingnews.com - April 17 at 1:12 AM
	Allscripts (MDRX) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 12 at 8:12 PM
	DIGITAL HEALTH BRIEFING: Google, AMA launch interoperability challenge — Doctor On Demand rolls out location ... www.businessinsider.com - April 12 at 8:56 AM
	Short Interest in Allscripts (MDRX) Increases By 29.0% www.americanbankingnews.com - April 12 at 2:17 AM
	Allscripts (MDRX) Lifted to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 11 at 6:45 PM
	Allscripts to release first-quarter 2018 financial results May 3 finance.yahoo.com - April 9 at 5:11 PM
	Dougherty & Co Reiterates Buy Rating for Allscripts (MDRX) www.americanbankingnews.com - April 8 at 10:08 AM
	Cantor Fitzgerald Reiterates Buy Rating for Allscripts (MDRX) www.americanbankingnews.com - April 5 at 1:57 PM
	Allscripts (MDRX) Downgraded by BidaskClub www.americanbankingnews.com - April 5 at 12:30 AM
	Allscripts (MDRX) Downgraded by TheStreet www.americanbankingnews.com - April 4 at 12:49 PM
	ValuEngine Lowers Allscripts (MDRX) to Sell www.americanbankingnews.com - April 3 at 11:31 PM
	Global Big Data in Healthcare Market 2017-2025 Featuring Key Players - McKesson, Allscripts, Epic Systems, Cerner ... globenewswire.com - April 3 at 5:24 PM
	Stratice Healthcare achieves Certification through the Allscripts Developer Program for eOrdersPlus globenewswire.com - April 2 at 5:17 PM
	Hyland completes acquisition of OneContent from Allscripts www.prnewswire.com - April 2 at 5:17 PM
	Allscripts closes OneContent business to Hyland Software, Inc. finance.yahoo.com - April 2 at 5:16 PM
	Allscripts (MDRX) Expected to Post Quarterly Sales of $533.09 Million www.americanbankingnews.com - April 2 at 4:58 AM
	Allscripts Healthcare Solutions Inc (MDRX) Expected to Post Earnings of $0.17 Per Share www.americanbankingnews.com - March 31 at 5:21 AM
	Allscripts Healthcare Solutions (MDRX) Stock Rating Lowered by SunTrust Banks www.americanbankingnews.com - March 28 at 3:14 PM
	Free Research Report as Allscripts’ Quarterly Revenues Jumped 22% and Adjusted EPS Surged 29% finance.yahoo.com - March 28 at 8:41 AM
	Allscripts Healthcare Solutions (MDRX) Earns Buy Rating from Analysts at Bank of America www.americanbankingnews.com - March 24 at 9:28 PM
	RBC Sees 4 Software Stocks as Potential Takeover Candidates - 24/7 Wall St. 247wallst.com - March 21 at 9:10 AM
	Oversold Conditions For Allscripts Healthcare Solutions (MDRX) - Nasdaq www.nasdaq.com - March 21 at 9:10 AM
	Why Is Allscripts (MDRX) Down 11.3% Since its Last Earnings Report? - Nasdaq www.nasdaq.com - March 19 at 8:34 AM
	Why Is Allscripts (MDRX) Down 11.3% Since its Last Earnings Report? finance.yahoo.com - March 19 at 8:34 AM
	Allscripts Healthcare Solutions Inc (MDRX) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 18 at 7:42 PM
	Is the Tax Repeal Only Glitter and No Gold for MedTech? finance.yahoo.com - March 16 at 6:18 PM
	Zacks: Analysts Expect Allscripts Healthcare Solutions Inc (MDRX) Will Announce Quarterly Sales of $533.39 Million www.americanbankingnews.com - March 16 at 7:32 AM
	Allscripts Healthcare Solutions Inc (MDRX) President Sells $202,950.00 in Stock www.americanbankingnews.com - March 15 at 8:42 PM
	Insider Selling: Allscripts Healthcare Solutions Inc (MDRX) EVP Sells 5,000 Shares of Stock www.americanbankingnews.com - March 15 at 8:28 PM
	Allscripts Healthcare Solutions (MDRX) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 14 at 6:38 PM
	Hyland Software, Inc. -- Moody's affirms Hyland's B2 CFR after debt-funded acquisition finance.yahoo.com - March 8 at 6:24 PM
	Allscripts (MDRX) Launches Avenel to Revamp EHR Platform finance.yahoo.com - March 7 at 8:31 AM
	Allscripts Healthcare Solutions' (MDRX) "Buy" Rating Reiterated at Cantor Fitzgerald www.americanbankingnews.com - March 6 at 3:28 PM
	Allscripts Healthcare Solutions Inc (MDRX) Shares Sold by Tamarack Advisers LP www.americanbankingnews.com - March 6 at 10:30 AM
	Allscripts, Lyft partner on health care transportation - MarketWatch www.marketwatch.com - March 6 at 8:28 AM
	Allscripts launches industry's first machine learning EHR - GlobeNewswire (press release) www.globenewswire.com - March 6 at 8:28 AM
	Allscripts launches industry’s first machine learning EHR finance.yahoo.com - March 6 at 8:28 AM
	California Public Employees Retirement System Boosts Stake in Allscripts Healthcare Solutions Inc (MDRX) www.americanbankingnews.com - March 6 at 5:26 AM
	Lyft Looks to Pioneer the Future of Ride-Hailing www.msn.com - March 5 at 5:42 PM
	Lyft and Allscripts want to make it easier to get people to the doctor's office finance.yahoo.com - March 5 at 5:42 PM
	Allscripts, Lyft partner on health care transportation finance.yahoo.com - March 5 at 5:42 PM
	Millrace Asset Group Inc. Has $1.70 Million Stake in Allscripts Healthcare Solutions Inc (MDRX) www.americanbankingnews.com - March 5 at 12:54 PM
	Martingale Asset Management L P Grows Stake in Allscripts Healthcare Solutions Inc (MDRX) www.americanbankingnews.com - March 5 at 10:14 AM
	Allscripts and Lyft partner to eliminate transportation barriers to healthcare - GlobeNewswire (press release) globenewswire.com - March 5 at 8:33 AM
	[$$] Patients Missing Doctor Visits Get Helping Hand finance.yahoo.com - March 5 at 8:33 AM
	Lyft and Allscripts want to make it easier to get people to the doctor's office finance.yahoo.com - March 5 at 8:33 AM
	Allscripts and Lyft partner to eliminate transportation barriers to healthcare finance.yahoo.com - March 5 at 8:33 AM

Allscripts (NASDAQ:MDRX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Allscripts (NASDAQ:MDRX) Income Statement, Balance Sheet and Cash Flow Statement

Allscripts (NASDAQ MDRX) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff